Prevail Venture Capital today highlighted an announcement from Paradromics, a Prevail Venture Capital portfolio company, which said it received FDA approval to expand recruitment for its Connexus® brain-computer interface clinical study nationwide.
The company's announcement names the FDA as the source of the approval. It describes the change as an expansion of clinical study recruitment to a nationwide scope. MobiHealthNews also reported the news.
Connect with Us